Skip to main content Accessibility help
×
Home

Management of acute agitation in psychosis: an evidence-based approach in the USA

  • Justin J. Schleifer

Summary

Agitation in psychiatric settings, particularly in psychosis, presents a staggering challenge for clinicians, who must both manage the patient's acute symptoms and simultaneously make an accurate diagnosis. Too often, the management of the former confounds the latter. Patients are very often sedated medically, which masks their underlying condition, rendering accurate diagnosis delayed and inherently difficult. Significant data are available regarding both pharmacological and non-pharmacological interventions for agitation that maximise symptom control while minimising confounding side-effects. In this article, a review of the historical evolution of agitation management in psychotic illness is presented, followed by an evidence-based clinical guideline for managing agitation in psychosis in the USA.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Management of acute agitation in psychosis: an evidence-based approach in the USA
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Management of acute agitation in psychosis: an evidence-based approach in the USA
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Management of acute agitation in psychosis: an evidence-based approach in the USA
      Available formats
      ×

Copyright

Corresponding author

Dr Justin Schleifer, Department of Psychiatry and Human Behavior, Box G-BH, Brown University, Providence, RI 02912, USA. Email: Justin_Schleifer@Brown.edu

Footnotes

Hide All

For a commentary on this article see 101–103, this issue.

Declaration of Interest

None.

Footnotes

References

Hide All
Abdelmawla, N, Mitchell, A (2006) Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms. Advances in Psychiatric Treatment 12: 3544.
Aleman, A, Kahn, RS (2001) Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. European Neuropsychopharmacology 11: 289–93.
Allen, MH (2000) Managing the agitated psychotic patient: a reappraisal of the evidence. Journal of Psychiatry 61 (suppl 14): 1120.
Altamura, AC, Sassella, F, Santini, A et al (2003) Intramuscular preparations of antipsychotics: uses of relevance in clinical practice. Drugs 63: 493512.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA.
Andrezina, R, Josiassen, RC, Marcus, RN et al (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berlin) 188: 281–92.
Battaglia, J, Lindborg, SR, Alaka, K et al (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine 21: 192–8.
Battaglia, J (2004) Intramuscular olanzapine: treating acute agitation in psychosis and bipolar mania. Current Psychiatry 3: 76–8.
Battaglia, J (2005) Pharmacologic management of acute agitation. Drugs 65: 1207–22.
Bellnier, TJ (2002) Continuum of care: stabilizing the acutely agitated patient. American Journal of Health-system Pharmacy 59 (suppl 5): s128.
Bristol-Myers Squibb (2003) Aripiprazole (Abilify) Package Insert. Bristol-Myers Squibb.
Buckley, PF, Noffsinger, SG, Smith, DA et al (2003) Treatment of the psychotic patient who is violent. Psychiatric Clinics of North America 26: 231–72.
Burris, KD, Molski, TF, Xu, C et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302: 381–9.
Canas, F (2007) Management of agitation in the acute psychotic patient: efficacy without excessive sedation. European Neuropsychopharmacology 17 (suppl 2): s10814.
Chengappa, KNR, Goldstein, JM, Greenwood, M et al (2003) A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clinical Therapeutics 25: 530–41.
Citrome, L (2004a) New treatments for agitation. Psychiatric Quarterly 75: 197213.
Citrome, L, Brook, S, Warrington, L et al (2004b) Ziprasidone versus haloperidol for the treatment of agitation. Annals of Emergency Medicine 44 (suppl): S22.
Citrome, L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry 68: 1876–85.
Cohen-Mansfield, J (1986) Agitated behavior in the elderly: a conceptual review. Journal of the American Geriatrics Society 34: 711–21.
Corrigan, JD (1989) Development of a scale for assessment of agitation following traumatic brain injury. Journal of Clinical and Experimental Neuropsychology 11: 261–77.
Currier, GW, Allen, MH (2000) Physical and chemical restraint in the psychiatric emergency service. Psychiatric Services 51: 717–9.
Currier, GW, Simpson, GM (2001) Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry 62: 153–7.
Currier, G, Allen, MH, Bunney, EB et al (2004a) Novel therapies for treating acute agitation. Journal of Emergency Medicine 27 (suppl 1): S138.
Currier, GW, Chou, JCY, Feifel, D et al (2004b) Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Journal of Clinical Psychiatry 65: 386–94.
Currier, G, Trenton, AJ, Walsh, PG et al (2006a) A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. Journal of Psychiatric Practice 12: 223–8.
Currier, GW, Medori, (2006b) Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. Journal of Psychiatric Practice 12: 3040.
Currier, GW, Citrome, LL, Zimbroff, DL et al (2007) Intramuscular aripiprazole in the control of agitation. Journal of Psychiatric Practice 3: 159–69.
Daniel, DG, Potkin, SG, Reeves, KR et al (2001) Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berlin) 155: 128–34.
Daniel, DG, Zimbroff, DL, Swift, RH et al (2004) The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. International Clinical Psychopharmacology 19: 915.
De Fruyt, Demyttenaere K (2004) Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. European Psychiatry 19: 243–9.
Downey, LV, Zun, LS, Gonzales, SJ (2007) Frequency of alternative to restraints and seclusion and uses of agitation reduction techniques in the emergency department. General Hospital Psychiatry 29: 470–4.
DuBuske, LM (1999) Second-generation antihistamines: the risk of ventricular arrhythmias. Clinical Therapeutics 21: 281–95.
Eli Lilly (2006) Olanzapine (Zyprexa) US Prescribing Information. Eli Lilly.
Eli Lilly (2008) Highlights of Prescribing Information: Zyprexa (Olanzapine) Tablets, Zyprexa Zydis (Olanzapine) Orally Disintegrating Tablets, Zyprexa Intramuscular (Olanzapine) for Injection. Product Information, Revised March 10, 2008. Eli Lilly (http://pi.lilly.com/us/zyprexa-pi.pdf).
Escobar, R, San, L, Perez, V et al (2008) Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results form NATURA study [in Spanish]. Actas Españolas de Psiquiatría 36: 151–7.
Expert Consensus Panel for Behavioral Emergencies (2005) The expert consensus guideline series. Treatment of behavioral emergencies 2005. Journal of Psychiatric Practice 11 (suppl 1): 5108.
Fisher, WA (1994) Restraint and seclusion: a review of the literature. American Journal of Psychiatry 15: 1584–91.
Foster, S, Kessel, J, Berman, ME et al (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology 12: 175–9.
Ganesan, ML, Bilsker, D, Khanbhai, I (2005) Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. International Journal of Psychiatry in Clinical Practice 9: 199203.
Glassman, AH (2001) Antipsychotic drugs: prolonged QTc interval, Torsades de pointes, and sudden death. American Journal of Psychiatry 158: 1774–82.
Greenblatt, DJ, Blaskovich, PD, Nuwayser, ES et al (2005) Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. Journal of Pharmacology 45: 1288–93.
Hatta, K, Kawabata, T, Yoshida, K et al (2008) Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. General Hospital Psychiatry 30: 367–71.
Karagianis, JL, Dawe, IC, Thakur, A et al (2001) Rapid tranquilization with olanzapine in acute psychosis: a case series. Journal of Clinical Psychiatry 62 (suppl 2): 12–6.
Kay, SR, Fiszbein, A, Opler, LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13: 261–76.
Kinon, BJ, Stauffer, VL, Kollack-Walker, S et al (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Psychopharmacology 28: 601–7.
Kopecky, HJ, Kopecky, CR, Yudofsky, SC (1998) Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients. Psychiatric Quarterly 69: 301–23.
Lejeune, J, Larmo, I, Chrzanowski, W et al (2004) Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. International Clinical Psychopharmacology 19: 259–69.
Leonard, BE (1992) Fundamentals of Psychopharmacology. John Wiley & Sons.
Lesem, MD, Zajecka, JM, Swift, RH et al (2001) Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry 62: 12–8.
Lindenmayer, J (2000) The pathophysiology of agitation. Journal of Clinical Psychiatry 61 (suppl 14): 510.
Marder, SR (2006) A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry 67 (suppl 10): 1321.
McAllister-Williams, RH, Ferrier, IN (2002) Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry 180: 485–9.
McCue, RE, Waheed, R, Urcuyo, L et al (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 189: 433–40.
Meehan, K, Zhang, F, David, S et al (2001) A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology 21: 389–97.
Mendelowitz, A (2004) The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Annals of Clinical Psychiatry 16: 145–54.
Mendoza, R, Djenderedjian, AH, Adams, J et al (1987) Midazolam in acute psychotic patients with hyperarousal. Journal of Clinical Psychiatry 48: 291–2.
Miller, DD (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Primary Care Companion to the Journal of Clinical Psychiatry 6 (suppl 2): 37.
Mohr, P, Pecenák, J, Svestka, J et al (2005) Treatment of acute agitation in psychotic disorders. Neuroendocrinology Letters 26: 327–35.
Montout, C, Casadebaig, F, Lagnaoui, R et al (2002) Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research 57: 147–56.
National Collaborating Centre for Nursing and Supportive Care (2005) Violence: The Short-term Management of Disturbed/Violent Behaviour in In-Patient Psychiatric Settings and Emergency Departments (Clinical Practice Guideline 25). National Institute for Health and Clinical Excellence (http://www.nice.org.uk/nicemedia/live/10964/29719/29719.pdf).
Ness, G, House, A, Ness, AR (2000) Aggression and violent behaviour in general practice: population based survey in the north of England. BMJ 320: 1447–8.
Pereira, S, Paton, C, Walkert, LM et al (2005) Treatment of acute behavioural disturbance: a UK national survey of rapid tranquillisation. Journal of Psychiatric Intensive Care 1: 84–8.
Petit, J (2005) Management of the acutely violent patient. Psychiatric Clinics of North America 28: 701–11.
Pfizer (2009) Highlights of Prescribing Information: Geodon (Ziprasidone HCL) Capsules, Geodon (Ziprasidone Mesylate) Injection for Intramuscular Use. Product Information, Revised May (http://www.pfizer.com/files/products/uspi_geodon.pdf).
Preval, H, Klotz, SG, Southard, R et al (2005) Rapid-acting intramuscular ziprasidone in the psychiatric emergency service: a naturalistic violence. General Hospital Psychiatry 27: 140–4.
Raja, M, Azzoni, A (2001) Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology 4: 393–7.
Raja, M, Azzoni, A (2003) Comparison of three antipsychotics in the emergency room setting. Human Psychopharmacology 18: 447–52.
Ray, WA, Meredith, S, Thapa, PB et al (2001) Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 58: 1161–7.
Tran-Johnson, TK, Sack, DA, Marcus, RN et al (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind placebo controlled trial. Journal of Clinical Psychiatry 68: 111–9.
TREC Collaborative Group (2003) Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 327: 708–11.
Tulloch, KJ, Zed, PJ (2004) Intramuscular olanzapine in the management of acute agitation. Annals of Pharmacotherapy 38: 2128–35.
Van Schaick, EA, Lechat, P, Remmerie, BM et al (2003) Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clinical Therapeutics 25: 1687–99.
Villari, V, Rocca, P (2008) Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32: 405–13.
Wise, R (2000) New restraint standards will change your practice. ED Management 12: 93–5.
Wright, P, Birkett, M, David, SR et al (2001) Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry 158: 1149–51.
Wright, P, Meehan, K, Birkett, M et al (2003) A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 25: 1420–8.
Yudofsky, SC, Kopecky, HJ, Kunik, M et al (1997) The Overt Agitation Severity Scale for the objective rating of agitation. Journal of Neuropsychiatry and Clinical Neurosciences 9: 541–8.
Zimbroff, DL, Marcus, RN, Manos, G et al (2007) Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. Journal of Psychopharmacology 27: 171–6.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Management of acute agitation in psychosis: an evidence-based approach in the USA

  • Justin J. Schleifer
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *